We can’t show the full text here under this license. Use the link below to read it at the source.
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise : 6‐month follow‐up from US real‐world data
Medication adherence and continuation in type 2 diabetes patients starting dulaglutide versus semaglutide and exenatide over 6 months in US real-world data
AI simplified
Abstract
At 6 months, 59.7% of dulaglutide users were adherent to treatment, compared to 42.7% for semaglutide and 58.1% for exenatide BCise.
- Dulaglutide users demonstrated significantly higher adherence rates than both semaglutide and exenatide BCise users.
- Persistence with dulaglutide was higher, as indicated by a lower likelihood of therapy discontinuation compared to semaglutide and exenatide BCise.
- The hazard ratio for discontinuation was 0.71 for dulaglutide versus semaglutide and 0.59 for dulaglutide versus exenatide BCise, suggesting better persistence.
- Matched cohorts had similar baseline characteristics, with mean ages of 54 and 55 years for dulaglutide and semaglutide/exenatide BCise users, respectively.
AI simplified
Key numbers
59.7%
Adherence Increase
Dulaglutide users vs. semaglutide users at 6 months
0.71
Persistence Hazard Ratio
Cox regression analysis comparing dulaglutide to semaglutide
69.2%
Persistence Increase
Proportion of persistent dulaglutide users vs. semaglutide users at 6 months